Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001533
Status:
COMPLETED
Last Update Posted:
2006-07-17
First Post:
1999-11-03
Brief Title:
Treatment of T-Large Granular Lymphocyte T-LGL Lymphoproliferative Disorders With Cyclosporine
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Treatment of T-Large Granular Lymphocyte T-LGL Lymphoproliferative Disorders With Cyclosporine
Status:
COMPLETED
Status Verified Date:
1999-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
T Cell Large Granular Lymphocyte T-LGL Lymphoproliferative Disorders are a heterogeneous group of uncommon diseases which may involve a polyclonal or a monoclonal T cell population which bear characteristic surface markers corresponding to activated cytotoxic CD3 CD8 lymphocytes They are often associated with quite severe neutropenia anemia and thrombocytopenia which may be life-threatening There is some evidence that the abnormal cytotoxic lymphocyte population may cause the cytopenias by suppressing hematopoiesis although the mechanism is unclear Case reports suggest that immunosuppressive therapy directed toward T cells may reverse the cytopenia This pilot study involving up to 25 patients evaluates the clinical response to cyclosporine an immunosuppressive drug and seeks to elucidate the mechanism underlying the cytopenia
Detailed Description:
T Cell Large Granular Lymphocyte T-LGL Lymphoproliferative Disorders are a heterogeneous group of uncommon diseases which may involve a polyclonal or a monoclonal T cell population which bear characteristic surface markers corresponding to activated cytotoxic CD3 CD8 lymphocytes They are often associated with quite severe neutropenia anemia and thrombocytopenia which may be life-threatening There is some evidence that the abnormal cytotoxic lymphocyte population may cause the cytopenias by suppressing hematopoiesis although the mechanism is unclear Case reports suggest that immunosuppressive therapy directed toward T cells may reverse the cytopenia This pilot study involving up to 25 patients evaluates the clinical response to cyclosporine an immunosuppressive drug and seeks to elucidate the mechanism underlying the cytopenia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96-H-0142 | None | None | None |